InvestorsHub Logo
Followers 78
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: noretreat post# 1095

Thursday, 10/05/2017 2:31:14 PM

Thursday, October 05, 2017 2:31:14 PM

Post# of 3878
Well my concern was valid - Mgmt reports as it is

—-
Quote:
Israel's biopharmaceutical company Redhill (12.05%) today announced positive initial results in a Phase II trial of 12 mg of BEKINDA for the treatment of irritable bowel syndrome (IBS-D). (Compared with an average daily turnover of less than NIS 1 million in the past month). Beyond the possibility of a correction after a 30% rally in recent weeks, the fact that the company has made it clear that the significance of the data is not too high.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News